Considering the stronger growth inhibition aroused by TrxR1 specific inhibitor BBSKE in MCF-10AT and MCF-7 cells rather than MCF-10A cells, we hold that TrxR1 is an underlying target for managing mammary carcinoma. The gene discussed is TXNRD1; the disease is breast carcinoma.